VTv Therapeutics is discontinuing current clinical studies involving azeliragon, including the open-label extension study and Part B of the STEADFAST study.
在212例参与者中,99%的患者进入开放标签扩展研究中。
Of the 212 participants who completed the study, 99% entered the open-label extension study.
完成22周给药的患者,可继续参与开放标签的扩展研究。
The 32 patients who completed treatment were invited to continue in the open-label extension study.
VTv Therapeutics is discontinuing current clinical studies involving azeliragon, including the open-label extension study and Part B of the STEADFAST study.
This Phase III study(NCT02195479) is a randomized, open-label, multicenter study and includes 706 newly diagnosed patients with multiple myeloma who are ineligible for ASCT.
Inbrija was also studied in a Phase 3 long-term, active-controlled, randomized, open-label study(N=398) assessing safety and tolerability over one year.
This Phase III study(NCT02195479) is a randomized, open-label, multicenter study that included 706 newly diagnosed patients with multiple myeloma who are ineligible for ASCT.
The multi-national, randomized, open-label trial included 695 newly diagnosed GBM patients who were enrolled at 83 centers from July 2009 to December 2016.
In this randomised open-label trial, eligible patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions.
KarMMa is a pivotal, open-label, single-arm, multi-center phase 2 study evaluating the efficacy and safety of bb2121 in patients with relapsed and refractory multiple myeloma.
中文
Bahasa indonesia
日本語
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt